RxDoctor Payments Data

Billee Payne, NP

Nurse Practitioner · Elizabeth City, NCNPI 1780636084

Payments from drug & device makers

$4,855in general payments, 2019–2025

Across 286 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$675
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$621
  • AstraZeneca$591
  • Amgen$525
  • Actelion Pharmaceuticals US, Inc.$338
  • Pfizer$312
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,78599%
  • Education$701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,855 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,771
Medicare patients
15
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban471$418,175
XareltoRivaroxaban173$168,282
EntrestoSacubitril/Valsartan130$115,276
FarxigaDapagliflozin Propanediol87$74,407
Repatha SureclickEvolocumab57$47,799
JardianceEmpagliflozin55$42,182
JanuviaSitagliptin Phosphate29$25,529
OzempicSemaglutide26$23,673
AmbienZolpidem Tartrate20$12,372
RybelsusSemaglutide12$11,689
DapagliflozinDapagliflozin Propanediol17$8,212
VascepaIcosapent Ethyl14$7,415
CorlanorIvabradine Hcl12$6,529
Flecainide Acetate79$4,297
Metoprolol Succinate324$3,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$312$418,175471 claims
Johnson & JohnsonXarelto$675$168,282173 claims
NovartisEntresto$78$115,276130 claims
AstraZenecaFarxiga$591$74,40787 claims
Boehringer IngelheimJardiance$31$42,18255 claims
Novo NordiskOzempic, Rybelsus$216$35,36238 claims
MerckJanuvia$29$25,52929 claims
Sanofi-aventis U.S. LLCAmbien$96$12,37220 claims
AmgenCorlanor$525$6,52912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Elizabeth City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →